| Study | Reason for exclusion |
|---|---|
| Araujo 1999 | Not primary regimen |
| Asci 2002 | Not primary regimen |
| Baek 2004 | Not RCT |
| Bataille 2010 | Unequal concomitant regimen |
| Benfield 1999 | Randomised to OKT3 and CsA (not AZA and MMF) |
| Boletis 1999b | Not RCT |
| Brennan 2005 | Not comparison of interest |
| Cransberg 2007 | Not primary regimen, no comparison of interest |
| El‐Agroudy 2009 | Not primary regimen |
| Ettenger 1995 | Not comparison of interest |
| Griffin 2003 | Not primary regimen |
| Ha 2004 | Not primary regimen |
| Hernandez 2007 | No comparison of interest |
| Jain 2001 | Not primary regimen |
| Jirasiritham 2000 | Not primary regimen |
| Kasiske 1997 | Not RCT |
| Khosroshahi 2006a | not RCT |
| Kim 1999 | not RCT |
| Langman 1996 | Not primary regimen |
| Lezaic 2005 | Not primary regimen |
| Lison 2004 | Not comparison of interest |
| Makhdoomi 2005 | Not RCT |
| Mandelbaum 1998 | not RCT |
| Merion 2000 | Multi‐organ transplantation |
| Metcalfe 2002 | Not primary regimen |
| MMF 1998 | Not primary regimen |
| MO2ART Study 2003 | Not comparison of interest |
| Nowacka‐Cieciur 2000 | Not primary regimen, no comparison of interest |
| Oliveira 1999 | No RCT |
| Schurter 1997 | Not primary regimen |
| Smak Gregoor 2000 | Not primary regimen |
| Touchard 2005 | Not primary regimen |
| Tsinalis 2000 | Unequal concomitant regimen |
| Vacher‐Coponat 2006 | Unequal concomitant regimen |
| van der Mast 2000 | Not primary regimen |
| Vanrenterghem 1998 | Not comparison of interest |
| Woeste 2002 | Multi‐organ transplantation, unequal concomitant regimen |
| Wuthrich 2000 | Not primary regimen |
AZA ‐ azathioprine; CsA ‐ cyclosporin A; MMF ‐ mycophenolate mofetil; RCT ‐ randomised controlled trial
Legend: no RCT: study design not RCT or quasi‐RCT; multi‐organ transplantation: not solely kidney transplantation, exclusion of studies enrolling patients undergoing multi‐organ transplantation, e.g. simultaneous kidney‐pancreas transplantation; not primary regimen: the randomisation to MMF versus AZA was not performed at the time of transplantation, but subsequently during the maintenance phase (e.g. due to previous acute rejection, chronic allograft nephropathy, calcineurin‐inhibitor‐toxicity or in stable graft function status); no comparison of interest: randomised intervention not of interest for the review, i.e. not MMF versus AZA; unequal concomitant regimen, i.e. patients randomised to intervention and control were treated with different immunosuppressive regimens (e.g. MMF/cyclosporin A versus AZA/tacrolimus)